ANPEP and breast cancer: The removal of O-glycans was observed to selectively enhance the detection of CD13 in breast cancer CDX tissue by the anti-CD13 antibodies, particularly those with epitope-binding domains at the terminal ends of the CD13 protein (i.e., mAb 1–250, mAb 687–697, Figure 3E).